Today: 8 June 2026
Beam Therapeutics stock rises 5% after BofA lifts target to $45
6 January 2026
1 min read

Beam Therapeutics stock rises 5% after BofA lifts target to $45

by

New York, January 6, 2026, 13:08 (EST) — Regular session

  • Beam Therapeutics shares were up about 5% at $28.24 in midday trading after touching $30.49.
  • BofA analyst Alec Stranahan raised his target price to $45 from $43 and kept a buy rating, Futu News reported.
  • A fresh SEC filing showed an automatic insider sale tied to tax withholding under a pre-arranged trading plan.

Beam Therapeutics (BEAM.O) shares rose about 5% to $28.24 by early afternoon on Tuesday after Bank of America raised its price target to $45 from $43 and kept a buy rating, according to a note carried by Futu News. The stock opened at $26.64, hit a session high of $30.49 and traded about 1.1 million shares.

The move mattered because traders were pushing up gene-editing stocks broadly, a space that often moves on analyst calls and conference headlines early in the year. CRISPR Therapeutics (CRSP.O) rose about 4.4%, Intellia Therapeutics (NTLA.O) gained about 2.1%, Prime Medicine (PRME.O) added about 2.7% and Editas Medicine (EDIT.O) was up about 1.5%.

Beam is developing precision genetic medicines using base editing, a form of gene editing aimed at making single-letter changes in DNA without cutting both strands. The Cambridge, Massachusetts-based company’s pipeline includes programs in diseases such as sickle cell disease and alpha-1 antitrypsin deficiency, a genetic disorder that can damage the lungs and liver.

Investors are also looking ahead to the J.P. Morgan Healthcare Conference, a major annual forum for biotech updates. Beam said Chief Executive John Evans is scheduled to present on Jan. 13 at 5:15 p.m. PT in San Francisco, with a webcast available on the company’s website.

A Form 4 filing on Monday showed Chief Legal Officer Christine Bellon sold 1,254 shares on Dec. 31 at $27.10 in an automatic transaction tied to restricted stock vesting. The filing said the shares were sold “to cover tax withholding obligations” under a Rule 10b5-1 plan — a pre-arranged trading program that lets insiders set trades in advance.

But Beam remains a development-stage biotech with no approved products, leaving the stock sensitive to trial safety signals, regulatory feedback and timelines that can slip. Any surprise dilution or a setback in clinical work can quickly reverse sentiment.

Shan Ahmed Khan Latest posts

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

  1. Inno Holdings Soared Nearly 20 Times—AI Deal Includes a Caveat
  2. Palantir’s $200 Target Meets Doubts on AI Growth
  3. Netflix stock drop gives fresh signal on streaming leader
  4. Wall Street’s Chip Rebound Lifts Nasdaq — Inflation Test Comes Next

Stock Market Today

  • SPTE ETF Sees Unusual Volume Surge on Monday, Led by Nvidia and Micron
    June 8, 2026, 3:11 PM EDT. The SP Funds S&P Global Technology ETF (SPTE) experienced unusually high trading volume Monday afternoon, hitting over 247,000 shares versus its three-month average of 45,000. The ETF's shares rose 2.9%. Key contributors included Nvidia, up 1.6% on 87.3 million shares, and Nokia, up 2% on 81.1 million shares. Micron Technology led gains, climbing roughly 10%, while Ciena lagged, down 5.7%. This volume spike highlights shifting investor interest in technology sector components within the SPTE ETF.

Latest articles

Nu Shares Drop, $1 Billion Buyback Doesn’t Ease Market

Nu Shares Drop, $1 Billion Buyback Doesn’t Ease Market

8 June 2026
Nu Holdings shares slid 3.1% to $11.60 as investors weighed CFO transition risks and rising credit costs, erasing last week’s 4.1% buyback-driven bounce; BofA downgraded the stock to Underperform with a $10 target, citing uncertainty from Lago’s exit, while Nu’s $1B buyback failed to stem a 10.7% weekly drop and 30.7% year-to-date decline, leaving shares just above their 52-week low.
Inno Holdings Soared Nearly 20 Times—AI Deal Includes a Caveat

Inno Holdings Soared Nearly 20 Times—AI Deal Includes a Caveat

8 June 2026
Inno Holdings shares soared twentyfold to $20.97 after announcing a $3 million AI sales agent deal for its used mobile phone business, but investor risks remain with a recent $60 million at-the-market stock program and ongoing going-concern warnings in filings, as the project is still in early development and not yet commercially launched.
Emirates Cuts A380 Flights, Raising Concerns Over Summer Airfare

Emirates Cuts A380 Flights, Raising Concerns Over Summer Airfare

8 June 2026
Emirates slashed June A380 flights on 10 major routes as soaring fuel costs and Middle East airspace disruption forced airlines to cut capacity, prompting IATA to halve its 2026 global profit forecast to $23 billion from $41 billion, with industry-wide seat reductions and rising fares expected as carriers struggle to absorb shocks during peak travel.
Wall Street Watches Microsoft’s $37 Billion AI Bet

Wall Street Watches Microsoft’s $37 Billion AI Bet

8 June 2026
Microsoft shares fell 1.5% to $410.30 as investors weighed bullish analyst calls and NHS England’s Copilot rollout against concerns that surging AI revenue—now at a $37 billion run rate—may not outpace rising costs and margin pressure from heavy infrastructure investment.
Cerebras shares jump as Wall Street eyes AI chipmaker’s Nvidia bid

Cerebras shares jump as Wall Street eyes AI chipmaker’s Nvidia bid

8 June 2026
Cerebras shares soared about 20% to $241.44 after Wall Street analysts initiated coverage post-IPO, citing rapid demand for fast AI inference and partnerships with OpenAI and AWS; Needham set a $300 price target, while the average analyst forecast reached $295, as chip stocks broadly rebounded and the PHLX Semiconductor Index jumped over 6%.
Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure
Previous Story

Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom
Next Story

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Go toTop